Search

Your search keyword '"Kvedariene V"' showing total 480 results

Search Constraints

Start Over You searched for: Author "Kvedariene V" Remove constraint Author: "Kvedariene V"
480 results on '"Kvedariene V"'

Search Results

51. Pharmacovigilance of drug allergy and hypersensitivity using the ENDA–DAHD database and the GA2LEN platform. The Galenda project

52. Correction to: Is diet partly responsible for differences in COVID-19 death rates between and within countries? (Clinical and Translational Allergy, (2020), 10, 1, (16), 10.1186/s13601-020-00323-0)

53. Aligning the good practice mask with the objectives of the European innovation partnership on active and healthy ageing

54. Correction to: Is diet partly responsible for differences in COVID-19 death rates between and within countries? (Clinical and Translational Allergy, (2020), 10, 1, (16), 10.1186/s13601-020-00323-0)

55. Treatment of allergic rhinitis during and outside the pollen season using mobile technology. A MASK study

57. Next-generation care pathways for allergic rhinitis and asthma multimorbidity: a model for multimorbid non-communicable diseases

58. Mobile technology offers novel insights into the control and treatment of allergic rhinitis: The MASK study

60. Pharmacologic and anti-IgE treatment of allergic rhinitis ARIA update (in collaboration with GA2LEN)

63. Aligning the good practice mask with the objectives of the European innovation partnership on active and healthy ageing

64. Treatment of allergic rhinitis during and outside the pollen season using mobile technology : A MASK study

67. Suspected Rivaroxaban-Induced Anaphylaxis Secondary to Ingestion of Rivaroxaban and Nimesulide Without Cross-Reactivity to Dabigatran – A Case Report

69. ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma

70. Next-generation ARIA care pathways for rhinitis and asthma: A model for multimorbid chronic diseases

71. 2019 ARIA Care pathways for allergen immunotherapy

72. Adherence to treatment in allergic rhinitis using mobile technology. The MASK Study

73. Guidance to 2018 good practice: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma

74. 2019 ARIA Care pathways for allergen immunotherapy

75. Next-generation care pathways for allergic rhinitis and asthma multimorbidity: A model for multimorbid non-communicable diseases—Meeting Report (Part 2)

76. ARIA pharmacy 2018 'Allergic rhinitis care pathways for community pharmacy': AIRWAYS ICPs initiative (European Innovation Partnership on Active and Healthy Ageing, DG CONNECT and DG Santé) POLLAR (Impact of Air POLLution on Asthma and Rhinitis) GARD Demonstration project

77. ARIA pharmacy 2018 'Allergic rhinitis care pathways for community pharmacy': AIRWAYS ICPs initiative (European Innovation Partnership on Active and Healthy Ageing, DG CONNECT and DG Santé) POLLAR (Impact of Air POLLution on Asthma and Rhinitis) GARD Demonstration project

78. Mobile Technology in Allergic Rhinitis: Evolution in Management or Revolution in Health and Care?

79. 2019 ARIA Care pathways for allergen immunotherapy [ARIA-Versorgungspfade für die Allergenimmuntherapie 2019]

80. Next-generation care pathways for allergic rhinitis and asthma multimorbidity: A model for multimorbid non-communicable diseases—Meeting Report (Part 1)

81. Mobile technology offers novel insights into the control and treatment of allergic rhinitis: The MASK study

82. ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma multimorbidity using real-world-evidence

85. Positioning the principles of precision medicine in care pathways for allergic rhinitis and chronic rhinosinusitis – A EUFOREA-ARIA-EPOS-AIRWAYS ICP statement

86. Erratum to: Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5)(Clin Transl Allergy (2016) 6 (29) DOI: 10.1186/s13601-016-0116-9)

87. Guidance to 2018 good practice: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma

88. ARIA pharmacy 2018 'Allergic rhinitis care pathways for community pharmacy'

89. Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018) : Change management in allergic rhinitis and asthma multimorbidity using mobile technology

90. Adherence to treatment in allergic rhinitis using mobile technology : The MASK Study

91. Next-generation care pathways for allergic rhinitis and asthma multimorbidity: A model for multimorbid non-communicable diseases—Meeting Report (Part 1)

92. Next-generation care pathways for allergic rhinitis and asthma multimorbidity: A model for multimorbid non-communicable diseases—Meeting Report (Part 2)

93. Next-generation ARIA care pathways for rhinitis and asthma: A model for multimorbid chronic diseases

94. Guidance to 2018 good practice: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma.

95. Treatment of allergic rhinitis using mobile technology with real-world data: The MASK observational pilot study

96. Transfer of innovation on allergic rhinitis and asthma multimorbidity in the elderly (MACVIA-ARIA) - EIP on AHA Twinning Reference Site (GARD research demonstration project)

97. Electronic Clinical Decision Support System for allergic rhinitis management: MASK e-CDSS

98. MASK 2017: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma multimorbidity using real-world-evidence

99. Transfer of innovation on allergic rhinitis and asthma multimorbidity in the elderly (MACVIA-ARIA) - EIP on AHA Twinning Reference Site (GARD research demonstration project)

100. ARIA Phase 4 (2018): Change management in allergic rhinitis and asthma multimorbidity using mobile technology

Catalog

Books, media, physical & digital resources